Key points are not available for this paper at this time.
Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV). A number of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63. Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is observed. X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead (15g) and the most potent analogues 3k and 3j, featuring a monofluoro substitution at para and meta positions of the benzyl ring, respectively. Finally, the less lipophilic bis(amide) 3e and methoxypyridine 5c exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yahira M. Báez-Santos
Purdue University West Lafayette
Scott J. Barraza
PTC Therapeutics (United States)
Michael W. Wilson
Broad Institute
Journal of Medicinal Chemistry
University of Michigan
Purdue University West Lafayette
Loyola University Chicago
Building similarity graph...
Analyzing shared references across papers
Loading...
Báez-Santos et al. (Wed,) studied this question.
synapsesocial.com/papers/6a1bfae627b545b111a94b94 — DOI: https://doi.org/10.1021/jm401712t